posted on 2022-02-02, 21:35authored byFabio Begnini, Stefan Geschwindner, Patrik Johansson, Lisa Wissler, Richard J. Lewis, Emma Danelius, Andreas Luttens, Pierre Matricon, Jens Carlsson, Stijn Lenders, Beate König, Anna Friedel, Peter Sjö, Stefan Schiesser, Jan Kihlberg
Upregulation of the
transcription factor Nrf2 by inhibition of
the interaction with its negative regulator Keap1 constitutes an opportunity
for the treatment of disease caused by oxidative stress. We report
a structurally unique series of nanomolar Keap1 inhibitors obtained
from a natural product-derived macrocyclic lead. Initial exploration
of the structure-activity relationship of the lead, followed by structure-guided
optimization, resulted in a 100-fold improvement in inhibitory potency.
The macrocyclic core of the nanomolar inhibitors positions three pharmacophore
units for productive interactions with key residues of Keap1, including
R415, R483, and Y572. Ligand optimization resulted in the displacement
of a coordinated water molecule from the Keap1 binding site and a
significantly altered thermodynamic profile. In addition, minor reorganizations
of R415 and R483 were accompanied by major differences in affinity
between ligands. This study therefore indicates the importance of
accounting both for the hydration and flexibility of the Keap1 binding
site when designing high-affinity ligands.